Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee.
Department of Medicine, University of Tennessee Medical Center, Knoxville, Tennessee.
Am J Perinatol. 2020 Jun;37(7):679-688. doi: 10.1055/s-0039-1688908. Epub 2019 May 19.
This study aimed to perform a systematic review of all studies reporting fetal outcomes following detoxification or tapering of opioid drugs during pregnancy.
PubMed, Scopus, Medline, and Google Scholar were searched, and only manuscripts clearly reporting pregnancy/fetal outcomes involving tapering or detoxification from opioid drugs were included. Only pregnancies managed after 1980 were included (when antenatal fetal surveillance became more routine). Collected data included study design, location, years patients were managed, number of patients who were tapered or detoxified, method of tapering, and pregnancy outcome.
A total of 14 publications met the criteria for review after evaluating more than 2,000 abstracts and 153 published manuscripts. In 1,097 pregnancies, based on mortality rate analyses and forest plots, no increased fetal risks due to tapering or detoxification from opioid drugs were identified. No increased risk of preterm delivery was found.
Pregnant women with opioid use disorder who are stable in a medication-assisted treatment program with behavioral health can be informed that tapering or full detoxification from opioid drugs does not increase the fetal risk of poor pregnancy outcome. Future research needs to answer the questions on maternal and long-term newborn consequences of tapering or detoxification versus long-term newborn consequences of continued chronic in utero opioid exposure.
本研究旨在对所有报告妊娠期阿片类药物解毒或减量后胎儿结局的研究进行系统评价。
检索了 PubMed、Scopus、Medline 和 Google Scholar,并仅纳入明确报告涉及阿片类药物减量或解毒的妊娠/胎儿结局的手稿。仅纳入 1980 年后管理的妊娠(当时产前胎儿监测变得更加常规)。收集的数据包括研究设计、地点、患者管理年限、接受减量或解毒的患者人数、减量方法以及妊娠结局。
在评估了 2000 多篇摘要和 153 篇已发表的手稿后,共有 14 篇出版物符合审查标准。基于死亡率分析和森林图,在 1097 例妊娠中,未发现阿片类药物减量或解毒会增加胎儿风险。未发现早产风险增加。
在药物辅助治疗计划中稳定且具有行为健康的阿片类药物使用障碍孕妇,可以告知她们阿片类药物减量或完全解毒不会增加不良妊娠结局的胎儿风险。未来的研究需要回答关于减量或解毒与持续慢性宫内阿片类药物暴露对母婴和长期新生儿后果的问题。